Page 44 - Alkermes News Today

Most antipsychotics have weight-related and metabolic side effects. This study shines a light on the relationship of dose and weight for each agent to help inform which antipsychotic to prescribe.

/PRNewswire/ -- The ERP Biomarker Qualification Consortium announced today the successful completion of a pharma industry-sponsored study to measure the...

Ketamine combined with psychotherapy yields significant improvements in symptoms of posttraumatic stress disorder, a new meta-analysis suggests.

NORTHAMPTON, MA / ACCESSWIRE / February 23, 2023 / Alkermes:Originally published by Boston Business Journal on December 22, 2022It's no surprise that a rising number of employees are reporting burnout

- Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 - - Achieved LYBALVI® Net Sales of $96.0 Million in First Full Year

DUBLIN--(BUSINESS WIRE)--The "Combination Product Services Market by Type of Device Service Focus Area, Company Size, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.The "Combination Product Services Market 2022-2035" report fe...

Dublin, Feb. 14, 2023 (GLOBE NEWSWIRE) -- The "Combination Product Services Market by Type of Device Service Focus Area, Company Size, and Key...

/PRNewswire/ -- The "Combination Product Services Market by Type of Device Service Focus Area, Company Size, and Key Geographical Regions: Industry Trends and...

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 16, 2023 to discuss the

New research questions whether long-acting injectable antipsychotics are better than oral medications in preventing treatment discontinuation in early-phase schizophrenia.